Products
Pre-made Teprotumumab benchmark antibody ( Whole mAb, anti-IGF1R therapeutic antibody, Anti-IGFR/CD221/IGFIR/JTK13 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-564
Pre-Made Teprotumumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-564-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Teprotumumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody |
| INN Name | Teprotumumab |
| Target | IGF1R |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2009 |
| Year Recommended | 2010 |
| Companies | Genmab;Roche;Horizon Therapeutics plc |
| Conditions Approved | Graves ophthalmopathy |
| Conditions Active | Diffuse scleroderma |
| Conditions Discontinued | Diabetic macular oedema;Advanced breast cancer;Hodgkin's disease;Non-Hodgkin's lymphoma;Non-small cell lung cancer;Sarcoma;Solid tumours |
| Development Tech | Medarex UltiMAb Mouse |
<